Here's Why I'd Sell Nebius Stock and Buy Astera Labs Instead

Astera Labs reported Q1 2026 revenue of $308.4 million, up 93% year over year and 14% sequentially, with GAAP operating income of $61.8 million and net income of $80.3 million. Management guided Q2 revenue to $355 million-$365 million versus prior consensus near $310 million, while Nebius was criticized as trading at roughly 99x trailing sales on about $530 million of revenue. The article favors Astera Labs for current profitability and visible hyperscaler demand over Nebius's more speculative valuation.

Analysis

The market is rewarding AI exposure that converts capex into visible earnings, not just narrative optionality. That creates a structural relative-value problem for NBIS: when the capital intensity is high and the equity is priced for flawless multi-year utilization, even strong operating results can underwhelm because the incremental dollar of value creation accrues slowly versus the multiple already embedded. In contrast, ALAB sits closer to the toll-road layer of the stack, where each additional rack, lane, and cluster interconnect tends to compound throughput with less incremental capital, so the earnings curve can stay ahead of sentiment for longer.

The second-order read-through is broader than these two names. If AI clusters keep growing in lane count and switching complexity, component suppliers with design wins become the real beneficiaries of hyperscaler capex, while GPU-cloud operators absorb more balance-sheet risk and customer concentration risk. That also implies a likely rotation within AI infrastructure away from the highest-duration stories and toward picks-and-shovels names with current margins, especially as investors become more selective about which vendors can monetize Gen 6 transitions without giving back economics to custom silicon efforts.

The main contrarian point is that ALAB is not cheap enough to treat as low-risk; it is simply less fragile than NBIS. The consensus may be underestimating how much of NBIS’s upside is already forward-loaded into the multiple, while overestimating how quickly ALAB’s current growth can decelerate if one or two hyperscaler ramps slip by a quarter. Near term, that means the spread can widen further on any beat-and-raise from ALAB, but over months the better tell is whether management can keep translating design wins into sustained free cash flow rather than one-time revenue spikes.

From a positioning perspective, this is a cleaner expression of quality within AI infrastructure than a directional beta bet on the whole theme. The most important catalyst is not just product launch cadence, but whether hyperscaler procurement converts from pilots to multi-quarter volume commitments; if that happens, ALAB’s earnings leverage can re-rate again even from here. If not, the stock likely de-risks via multiple compression before the story breaks, which is why the entry should be disciplined rather than chased.

Key Decisions for Investors

• Long ALAB vs short NBIS as a relative-value pair for 3-6 months; the thesis is that current earnings visibility and lower capital intensity deserve a premium while NBIS remains multiple-fragile if AI sentiment cools.
• Buy ALAB on pullbacks, not strength, targeting entries after post-earnings volatility or a 5-8% retrace; risk/reward favors owning visible growth with current profits, but only if the multiple resets modestly.
• Avoid initiating new NBIS longs here unless sizing is venture-style and time horizon is 2-3 years; upside exists, but near-term equity returns are highly dependent on flawless execution and continued multiple support.
• For more conservative exposure, pair a modest ALAB long with a short basket of high-duration AI infrastructure names that lack current profitability; this isolates the market’s preference for cash-generative picks-and-shovels over story stocks.
• If ALAB holds through the next catalyst with upside guidance intact, add on confirmation rather than anticipation; the best setup is a beat-and-raise cycle where revenue growth remains >50% and margin expansion proves the model can scale without dilution.